Metastatic melanoma is the most serious and life-threatening type of skin cancer and is associated with low survival rates. There are a variety of gene mutations that can lead to metastatic melanoma, but the most common is BRAF. Despite recent advancements, many patients with BRAF-mutant metastatic melanoma still face significant challenges managing their disease, and there remains a substantial need for treatments that delay disease progression and impact survival.
- Approximately 50% of metastatic melanoma cases have the BRAF gene mutation, a key target in the treatment of metastatic melanoma.[i]
- In metastatic melanoma, BRAF V600E and BRAF V600K account for approximately 92% of all BRAF mutations.1
- Approximately 1 person dies from melanoma every hour.[ii]
- The incidence of melanoma has more than doubled in the past 40 years.[iii]
On June 27, 2018, the U.S. FDA approved BRAFTOVI® (encorafenib) capsules in combination with MEKTOVI® (binimetinib) tablets for the treatment of patients with unresectable or metastatic melanoma with a BRAFV600E or BRAFV600K mutation, as detected by an FDA-approved test. BRAFTOVI is not indicated for the treatment of patients with wild-type BRAFmelanoma. This means now, physicians and patients have the option to consider treatment with this combination therapy.
